Tonghan Li, Xuan Zhao, Zhikai Xu, Fan Yang, Zhanfei Li, Xiangjun Bai, Hao Zhu, Hong Zhao, Yukun Liu, Yuchang Wang
{"title":"硒代蛋氨酸通过抑制ROS/NLRP3信号通路减轻败血症诱导的骨骼肌萎缩。","authors":"Tonghan Li, Xuan Zhao, Zhikai Xu, Fan Yang, Zhanfei Li, Xiangjun Bai, Hao Zhu, Hong Zhao, Yukun Liu, Yuchang Wang","doi":"10.1097/SHK.0000000000002690","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Sepsis-induced muscle atrophy (SIMA) significantly impairs patient quality of life, yet effective therapeutic strategies remain limited. This study aimed to investigate the protective effects of selenomethionine (Se-Met) on sepsis-induced skeletal muscle atrophy and explore the underlying molecular mechanisms, with the goal of providing a novel theoretical foundation and potential therapeutic approach for sepsis-associated muscle injury.</p><p><strong>Methods: </strong>A murine sepsis model was established via cecal ligation and puncture (CLP), followed by treatment with varying doses of Se-Met. Survival rate, body weight, skeletal muscle mass, and muscle strength were evaluated. Histological analysis (HE staining) was used to assess muscle fiber cross-sectional area. Protein expression levels of Atrogin-1, MuRF1, and pyroptosis-related markers (NLRP3, Caspase-1, GSDMD, IL-18, IL-1β) were examined via Western blot. In vitro, C2C12 myoblasts were stimulated with lipopolysaccharide (LPS) and treated with Se-Met to assess oxidative stress markers (ROS, MDA, SOD, GSH-Px), pyroptosis-related proteins, and inflammatory cytokines (e.g., IL-6, IL-18). ROS scavenger NAC, NLRP3 agonist, and ROS inducer were employed in mechanistic studies to further elucidate the molecular mechanisms.</p><p><strong>Results: </strong>Se-Met significantly improved survival, body weight, and muscle strength in septic mice, and alleviated skeletal muscle atrophy. Mechanistically, Se-Met inhibited the NLRP3/Caspase-1/GSDMD signaling axis, thereby reducing pyroptosis and the expression of inflammatory cytokines such as IL-6, IL-18, and IL-1β. Furthermore, Se-Met decreased ROS accumulation, enhanced antioxidant enzyme activities, and suppressed pyroptosis through regulation of the ROS/NLRP3 pathway, ultimately reducing protein degradation mediated by Atrogin-1 and MuRF1.</p><p><strong>Conclusion: </strong>This study demonstrates that Se-Met mitigates sepsis-induced skeletal muscle atrophy by exerting antioxidant effects, inhibiting pyroptosis, and modulating inflammatory responses. The findings highlight the critical role of the ROS/NLRP3 signaling pathway in the protective action of Se-Met, providing new experimental evidence for its potential application in sepsis and other oxidative stress-related diseases.</p>","PeriodicalId":21667,"journal":{"name":"SHOCK","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Selenomethionine Attenuates Sepsis-Induced Skeletal Muscle Atrophy by Inhibiting ROS/NLRP3 Signaling.\",\"authors\":\"Tonghan Li, Xuan Zhao, Zhikai Xu, Fan Yang, Zhanfei Li, Xiangjun Bai, Hao Zhu, Hong Zhao, Yukun Liu, Yuchang Wang\",\"doi\":\"10.1097/SHK.0000000000002690\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Sepsis-induced muscle atrophy (SIMA) significantly impairs patient quality of life, yet effective therapeutic strategies remain limited. This study aimed to investigate the protective effects of selenomethionine (Se-Met) on sepsis-induced skeletal muscle atrophy and explore the underlying molecular mechanisms, with the goal of providing a novel theoretical foundation and potential therapeutic approach for sepsis-associated muscle injury.</p><p><strong>Methods: </strong>A murine sepsis model was established via cecal ligation and puncture (CLP), followed by treatment with varying doses of Se-Met. Survival rate, body weight, skeletal muscle mass, and muscle strength were evaluated. Histological analysis (HE staining) was used to assess muscle fiber cross-sectional area. Protein expression levels of Atrogin-1, MuRF1, and pyroptosis-related markers (NLRP3, Caspase-1, GSDMD, IL-18, IL-1β) were examined via Western blot. In vitro, C2C12 myoblasts were stimulated with lipopolysaccharide (LPS) and treated with Se-Met to assess oxidative stress markers (ROS, MDA, SOD, GSH-Px), pyroptosis-related proteins, and inflammatory cytokines (e.g., IL-6, IL-18). ROS scavenger NAC, NLRP3 agonist, and ROS inducer were employed in mechanistic studies to further elucidate the molecular mechanisms.</p><p><strong>Results: </strong>Se-Met significantly improved survival, body weight, and muscle strength in septic mice, and alleviated skeletal muscle atrophy. Mechanistically, Se-Met inhibited the NLRP3/Caspase-1/GSDMD signaling axis, thereby reducing pyroptosis and the expression of inflammatory cytokines such as IL-6, IL-18, and IL-1β. Furthermore, Se-Met decreased ROS accumulation, enhanced antioxidant enzyme activities, and suppressed pyroptosis through regulation of the ROS/NLRP3 pathway, ultimately reducing protein degradation mediated by Atrogin-1 and MuRF1.</p><p><strong>Conclusion: </strong>This study demonstrates that Se-Met mitigates sepsis-induced skeletal muscle atrophy by exerting antioxidant effects, inhibiting pyroptosis, and modulating inflammatory responses. The findings highlight the critical role of the ROS/NLRP3 signaling pathway in the protective action of Se-Met, providing new experimental evidence for its potential application in sepsis and other oxidative stress-related diseases.</p>\",\"PeriodicalId\":21667,\"journal\":{\"name\":\"SHOCK\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-09-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"SHOCK\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/SHK.0000000000002690\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CRITICAL CARE MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"SHOCK","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/SHK.0000000000002690","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
Selenomethionine Attenuates Sepsis-Induced Skeletal Muscle Atrophy by Inhibiting ROS/NLRP3 Signaling.
Objective: Sepsis-induced muscle atrophy (SIMA) significantly impairs patient quality of life, yet effective therapeutic strategies remain limited. This study aimed to investigate the protective effects of selenomethionine (Se-Met) on sepsis-induced skeletal muscle atrophy and explore the underlying molecular mechanisms, with the goal of providing a novel theoretical foundation and potential therapeutic approach for sepsis-associated muscle injury.
Methods: A murine sepsis model was established via cecal ligation and puncture (CLP), followed by treatment with varying doses of Se-Met. Survival rate, body weight, skeletal muscle mass, and muscle strength were evaluated. Histological analysis (HE staining) was used to assess muscle fiber cross-sectional area. Protein expression levels of Atrogin-1, MuRF1, and pyroptosis-related markers (NLRP3, Caspase-1, GSDMD, IL-18, IL-1β) were examined via Western blot. In vitro, C2C12 myoblasts were stimulated with lipopolysaccharide (LPS) and treated with Se-Met to assess oxidative stress markers (ROS, MDA, SOD, GSH-Px), pyroptosis-related proteins, and inflammatory cytokines (e.g., IL-6, IL-18). ROS scavenger NAC, NLRP3 agonist, and ROS inducer were employed in mechanistic studies to further elucidate the molecular mechanisms.
Results: Se-Met significantly improved survival, body weight, and muscle strength in septic mice, and alleviated skeletal muscle atrophy. Mechanistically, Se-Met inhibited the NLRP3/Caspase-1/GSDMD signaling axis, thereby reducing pyroptosis and the expression of inflammatory cytokines such as IL-6, IL-18, and IL-1β. Furthermore, Se-Met decreased ROS accumulation, enhanced antioxidant enzyme activities, and suppressed pyroptosis through regulation of the ROS/NLRP3 pathway, ultimately reducing protein degradation mediated by Atrogin-1 and MuRF1.
Conclusion: This study demonstrates that Se-Met mitigates sepsis-induced skeletal muscle atrophy by exerting antioxidant effects, inhibiting pyroptosis, and modulating inflammatory responses. The findings highlight the critical role of the ROS/NLRP3 signaling pathway in the protective action of Se-Met, providing new experimental evidence for its potential application in sepsis and other oxidative stress-related diseases.
期刊介绍:
SHOCK®: Injury, Inflammation, and Sepsis: Laboratory and Clinical Approaches includes studies of novel therapeutic approaches, such as immunomodulation, gene therapy, nutrition, and others. The mission of the Journal is to foster and promote multidisciplinary studies, both experimental and clinical in nature, that critically examine the etiology, mechanisms and novel therapeutics of shock-related pathophysiological conditions. Its purpose is to excel as a vehicle for timely publication in the areas of basic and clinical studies of shock, trauma, sepsis, inflammation, ischemia, and related pathobiological states, with particular emphasis on the biologic mechanisms that determine the response to such injury. Making such information available will ultimately facilitate improved care of the traumatized or septic individual.